Drug candidates in clinical trials for Alzheimer’s disease

[1]  C. Jack,et al.  A phase 3 trial of IV immunoglobulin for Alzheimer disease , 2017, Neurology.

[2]  N. Hawkes.  Merck ends trial of potential Alzheimer’s drug verubecestat , 2017, British Medical Journal.

[3]  Shikha Prashad,et al.  Cognitive motor deficits in cannabis users , 2017, Current Opinion in Behavioral Sciences.

[4]  B. Cullen,et al.  Update on Alzheimer's Disease Therapy and Prevention Strategies. , 2017, Annual review of medicine.

[5]  A. Abbott,et al.  Failed Alzheimer’s trial does not kill leading theory of disease , 2016, Nature.

[6]  Michael Tanen,et al.  The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.

[7]  Roy W Jones,et al.  Drug development in Alzheimer’s disease: the path to 2025 , 2016, Alzheimer's Research & Therapy.

[8]  P. Takahashi,et al.  Active Vaccines for Alzheimer Disease Treatment. , 2016, Journal of the American Medical Directors Association.

[9]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[10]  A. Grimm,et al.  Alzheimer, mitochondria and gender , 2016, Neuroscience & Biobehavioral Reviews.

[11]  G. Logroscino,et al.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease , 2016, BioMed research international.

[12]  D. Hill,et al.  Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials , 2016, Alzheimer's Research & Therapy.

[13]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[14]  Jakub Jończyk,et al.  Therapeutic strategies for Alzheimer’s disease in clinical trials , 2016, Pharmacological reports : PR.

[15]  G. Gerhardt,et al.  Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression , 2015, Journal of neurochemistry.

[16]  Uwe Maskos,et al.  Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment , 2015, Neuropharmacology.

[17]  P. Spano,et al.  CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid , 2015, Neuroscience.

[18]  W. Fu,et al.  LC3 overexpression reduces Aβ neurotoxicity through increasing α7nAchR expression and autophagic activity in neurons and mice , 2015, Neuropharmacology.

[19]  H. Arai,et al.  Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. , 2015, Current Alzheimer research.

[20]  F. Grüninger.  Invited review: Drug development for tauopathies , 2015, Neuropathology and applied neurobiology.

[21]  Thomas C. Baddeley,et al.  Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer’s Disease , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[22]  N. Iwata,et al.  Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. , 2015, Journal of Alzheimer's disease : JAD.

[23]  R. Staff,et al.  Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[24]  A. Cesario,et al.  Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials. , 2014, Current pharmaceutical design.

[25]  R. Segurado,et al.  NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease , 2014, BMJ Open.

[26]  G. Logroscino,et al.  Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? , 2014, Expert opinion on biological therapy.

[27]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[28]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[29]  R. Mayeux,et al.  Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers , 2014 .

[30]  G. Logroscino,et al.  Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward , 2014, Expert review of clinical immunology.

[31]  D. Cribbs,et al.  Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines , 2014, Human vaccines & immunotherapeutics.

[32]  A. Othman,et al.  A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.

[33]  Stephen Todd,et al.  Survival in dementia and predictors of mortality: a review , 2013, International journal of geriatric psychiatry.

[34]  C. Lemere.  Immunotherapy for Alzheimer’s disease: hoops and hurdles , 2013, Molecular Neurodegeneration.

[35]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[36]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[37]  D. Nicholson,et al.  The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques , 2013, Acta Neuropathologica.

[38]  S. Kaveri.  Intravenous immunoglobulin: exploiting the potential of natural antibodies. , 2012, Autoimmunity reviews.

[39]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[40]  N. Tabet,et al.  Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.

[41]  D. Bertrand,et al.  EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors , 2012, Neuropharmacology.

[42]  S. Weggen,et al.  Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer’s Disease , 2011, Current neuropharmacology.

[43]  L. Schneider,et al.  Lack of evidence for the efficacy of memantine in mild Alzheimer disease. , 2011, Archives of neurology.

[44]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[45]  C. Volmar,et al.  Selective Antihypertensive Dihydropyridines Lower Aβ Accumulation by Targeting both the Production and the Clearance of Aβ across the Blood-Brain Barrier , 2011, Molecular medicine.

[46]  S. Gauthier,et al.  Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) , 2011, Archives of medical science : AMS.

[47]  Neil Upton,et al.  5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease , 2008, Neurotherapeutics.

[48]  S. Swedo,et al.  Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. , 2010, Journal of child and adolescent psychopharmacology.

[49]  Mark A. Smith,et al.  Faculty Opinions recommendation of Autophagy protects neuron from Abeta-induced cytotoxicity. , 2010 .

[50]  George T Grossberg,et al.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias , 2009, Clinical interventions in aging.

[51]  J. McCarthy,et al.  Presenilin-dependent regulated intramembrane proteolysis and γ-secretase activity , 2009, Cellular and Molecular Life Sciences.

[52]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[53]  P. Mehta,et al.  Intranasal insulin improves cognition and modulates β-amyloid in early AD , 2008, Neurology.

[54]  M. Gobbi,et al.  Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. , 2008, European journal of pharmacology.

[55]  M. Reger,et al.  Intranasal insulin improves cognition and modulates beta-amyloid in early AD. , 2008, Neurology.

[56]  M. Michaelis,et al.  Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. , 2007, European journal of pharmacology.

[57]  S. Wharton,et al.  A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. , 2007, Clinical neuropathology.

[58]  P. Tariot,et al.  Meta-analysis of six-month memantine trials in Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[59]  W. Wang,et al.  Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) , 2004, Neuroscience.

[60]  P. Dodd,et al.  Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease , 2004, Neurochemistry International.

[61]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[62]  H. Hippius,et al.  The discovery of Alzheimer's disease , 2003, Dialogues in clinical neuroscience.

[63]  H. Möller,et al.  Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease , 2002 .

[64]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[65]  G. Wenk,et al.  Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[67]  L. Frölich,et al.  A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease , 1999, Annals of the New York Academy of Sciences.

[68]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[69]  P. Blandina,et al.  Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. , 1998, Methods and findings in experimental and clinical pharmacology.

[70]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.